CA2428985C - Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers - Google Patents
Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers Download PDFInfo
- Publication number
- CA2428985C CA2428985C CA2428985A CA2428985A CA2428985C CA 2428985 C CA2428985 C CA 2428985C CA 2428985 A CA2428985 A CA 2428985A CA 2428985 A CA2428985 A CA 2428985A CA 2428985 C CA2428985 C CA 2428985C
- Authority
- CA
- Canada
- Prior art keywords
- acid
- ophthalmic solution
- bis
- solution
- phmb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/141—Biguanides, e.g. chlorhexidine
- A61L12/142—Polymeric biguanides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/143—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/143—Quaternary ammonium compounds
- A61L12/145—Polymeric quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/20—Organic compounds containing oxygen
- C11D3/22—Carbohydrates or derivatives thereof
- C11D3/221—Mono, di- or trisaccharides or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/37—Polymers
- C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C11D3/3723—Polyamines or polyalkyleneimines
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/26—Organic compounds containing oxygen
- C11D7/261—Alcohols; Phenols
Abstract
A contact lens solution comprising 0.0001 to 10 weight percent or a preservative enhancer chosen from the group consisting of: inositol; mannitol;
sorbitol; sucrose; dextrose; glycerin and propylene glycol; and at least 0.0001 weight percent of a cationic polymeric preservative, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
sorbitol; sucrose; dextrose; glycerin and propylene glycol; and at least 0.0001 weight percent of a cationic polymeric preservative, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
Description
V O (12/381(1 PCT/USO1/46344 IMPROVED OP!ITIIALMIC AND CONTACT LENS SOLUTIONS CONTAINING SIMPLE SACCIIARIDI-S AS
PRESERVATIVE ENILANCERS
Field of the Invention The present-invention relates to the field of ophthalmic solutions and their uses. In particular the invention relates to contact lens cleaning solutions, contact lens rinsing and storing solutions, solutions to deliver active pharmaceutical agents to the eye, solutions for disinfecting ophtalmic devices and the like.
Background The present invention relates to the field of ophthalmic solutions and especially to the aspects of preservative efficacy and comfort after prolonged use. These ophthalmic solutions have been used for some period of time and are available as over the counter products. Solutions that are used in direct contact with corneal tissue such as the delivery of active pharmaceutical agent to the eye, or indirectly, such as the cleaning, conditioning or storage of devices that will come in contact with corneal tissue, such as contact lenses, there is a need to insure that these solution do not introduce sources of bacterial or other microbial infection. Thus preservatives are included to reduce the viability of microbes in the solution and to lessen the chance of contamination of the solution by the user since many of the solutions are bought, opened, used, sealed and then reused.
State of the art preservative agents include polyhexamethylene biguanide (phmb), polyquad tr", chlorhexidine, and benzalkonium chloride, and the like, all of which at some concentration irritate corneal tissue and lead to user discomfort.
Therefore, a solution that employs a given amount of a preservative agent, but which is made more effective by addition of an agent that is not a preservative agent would be desired.
Summary of the Invention The present invention relates to improved ophthalmic solutions that employ inositol in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
The solutions specifically described herein have 0.001 to about 1 percent of inositol in combination with other active ingredients useful in ophthalmic solutions such as buffers, preservatives, surfactants, and antimicrobial agents, and with a low chloride concentration, less than about 0.2 percent by weight. It has been found, surprisingly that inositol, and other sugars including mannitol, sorbitol, sucrose, dextrose, glycerin and propylene glycol, effectively increase the antibacterial effect of preservatives in low salt (low chloride) conditions.
The preservatives that are specifically useful are cationic polymeric preservatives such as polyhexamethylene biguanide (phmb), polyquad tm, chlorhexidne, and benzalkonium chloride, as well as other cationic preservatives that may prove useful in the present invention as well. The cationic preservatives are used at effective amounts as preservatives, and in the instance of PHMB from 0.0001 percent by weight to higher levels of about 0.01 weight percent. Specifcally, The cationic polymeric preservative includes polymeric biguanides such as polymeric hexamethylene biguanides (PHMB), and combinations thereof. Such cationic polymeric biguanides, and water-soluble salts thereof, having the following formula:
X1 Z-NH C-NH-C-NHt Z-Xz NH NH
wherein Z is an organic divalent bridging group which may be the same or different throughout the polymer, n is on average at least 3, preferably on average 5 to 20, and X1 and X2 are NH2 and NH-C -NH-CN
NH
One preferred group of water-soluble polymeric biguanides will have number average molecular weights of at least 1,000 and more preferably will have number average molecular weights from 1,000 to 50,000. Suitable water-soluble salts of the free bases include, but are not limited to hydrochloride, borate, acetate, gluconate, sulfonate, tartrate and citrate salts.
The above-disclosed biguanides and methods of preparation are described in the literature. For example, U.S. Pat. No. 3,428,576 describes the preparation of polymeric biguanides from a diamine and salts thereof and a diamine salt of dicyanimide.
Most preferred are the polymeric hexamethylene biguanides, commercially available, for example, as the hydrochloride salt from Zeneca (Wilmington, Del.) under the trademark CosmocilTM CQ. Such polymers and water-soluble salts are referred to as polyhexamethylene (PHMB) or polyaminoptopyl biguanide (PAPB). The term polyhexamethylene biguanide, as used herein, is meant to encompass one or more biguanides have the following formula:
X1--E-Z-NH-C-NH-C-NH-}n z-X2 II II
NH NH
wherein Z, X1 and X2 are as defined above and n is from 1 to 500.
Depending on the manner in which the biguanides are prepared, the predominant compound falling within the above formula may have different X1 and X2 groups or the same groups, with lesser amounts of other compounds within the formula.
Such compounds are known and are disclosed in U.S. Pat. No. 4,758,595 and British 'O (12/38161 PCT/US01/46344 Patent 1,432,345. Preferably, the water-soluble salts are compounds where n has an average value of 2 to 15, most preferably 3 to 12.
It was found that an unexpected preservative efficacy was displayed when inositol was used in conjunction with the cationic preservative. The other components of the solution are used at levels known to those skilled in the art in order to improve the wearability of lenses and when used directly in the eye, to provide increased resistance to infection. Inositol used in ophthalmic solutions increases preservative efficacy in certain formulations, provides increased resistance to infection in corneal tissue, in certain formulations, and improves the quality of tears in certain formulations.
The formulations may also include buffers such as phosphates, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, and Tricine Surfactants that might be employed include polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils, but preerrably the polyethoxylated castor oils. These surfactants are commercially available.
The polyethoxylated castor oils are sold by BASF under the trademark Cremaphor.
Inositol, mannitol, sorbitol, sucrose, dextrose, glycerin, propylene glycol and the other agents used in the present invention are all commercially available, and well enough understood to be formulated into products within the scope of the invention by those skilled in the art.
The solutions of the present invention may contain other additives including but not limited to buffers, tonicity agents, demulcents, wetting agents, preservatives, sequestering agents (chelating agents), surface active agents, and enzymes.
Other aspects include adding to the solution from 0.001 to 1 weight percent chelating agent (preferably disodium EDTA) and/or additional microbicide, (preferably 0.00001 to 0.1 or 0.0000 1 to 0.01) weight percent polyhexamethylene biquanide (PHMBO, N-alkyl-2-pyrrolidone, chlorhexidine, polyquaternium- 1, hexetidine, bronopol, alexidine, low concentrations of hydrogen peroxide, and ophthalmologically acceptable salts thereof Ophthalmologically acceptable chelating agents useful in the present invention include amino carboxylic acid compounds or water-soluble salts thereof, including ethylenediaminetetraacetic acid, nitrilotriacetic acid, diethylenetriamine pentaacetic acid, hyd roxyethyl ethyl ened ia m i netriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol bis (beta-aminoethyl ether) in N, N, N', N' tetraacetic acid (EGTA), aminodiacetic acid and hydroxyethylamino diacetic acid. These acids can be used in the form of their water soluble salts, particularly their alkali metal salts.
Especially preferred chelating agents are the di-, tn- and tetra-sodium salts of ethylenediaminetetraacetic acid (EDTA), most preferably disodium EDTA
(Disodium Edetate).
Other chelating agents such as citrates and polyphosphates can also be used in the present invention. The citrates which can be used in the present invention include citric acid and its mono-, di-, and tri-alkaline metal salts. The polyphosphates which can be used include pyrophosphates, triphosphates, tetraphosphates, trimetaphosphates, tetrametaphosphates, as well as more highly condensed phosphates in the form of the neutral or acidic alkali metal salts such as the sodium and potassium salts as well as the ammonium salt.
The pH of the solutions should be adjusted to be compatible with the eye and the contact lens, such as between 6.0 to 8.0, preferably between 6.8 to 7.8 or between 7.0 to 7.6. Significant deviations from neutral (pH 7.3) will cause changes in the physical parameters (i.e. diameter) in some contact lenses. Low pH (pH less than 5.5) can cause burning and stinging of the eyes, while very low or very high pH (less than 3.0 or greater than 10) can cause ocular damage.
The additional preservatives employed in the present invention are known, such as polyhexamethylene biguanide, N-alkyl-2-pyrrolidone, chlorhexidine, polyhexamethylenebiguanide, alexidine, polyquaternium- 1, hexetidine, bronopol and a very low concentration of hydrogen peroxide, e.g., 30 to 200 ppm.
WO 02/38161 PCT/US01/.6344 The solutions of the invention are compatible with both rigid gas permeable and hydrophilic contact lenses during storage, cleaning, wetting, soaking, rinsing and disinfection.
A typical aqueous solution of the present invention may contain additional ingredients which would not affect the basic and novel characteristics of the active ingredients described earlier, such as tonicity agents, surfactants and viscosity inducing agents, which may aid in either the lens cleaning or in providing lubrication to the eye. Suitable tonicity agents include sodium chloride, potassium chloride, glycerol or mixtures thereof The tonicity of the solution is typically adjusted to approximately 240-310 milliosmoles per kilogram solution (mOsm/kg) to render the solution compatible with ocular tissue and with hydrophilic contact lenses. In one embodiment, the solution contains 0.01 to 0.2 weight percent sodium chloride.
The important factor is to keep the concentrations of such additives to a degree no greater than that would supply a chloride concentration of no greater than about 0.2 mole percent.
Suitable viscosity inducing agents can include lecithin or the cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose and methylcellulose in amounts similar to those for surfactants, above.
EXAMPLE I
TM
Formulations containing inositol (Spectrum) were prepared in a 0.2% phosphate buffer. The solutions were made isotonic with sodium chloride and preserved with polyhexamethylene biquanide at 0.0001 %. The pH was adjusted to 7.2 with either I
N sodium hydroxide or 1 N hydrochloric acid. The in vitro microbicidal activity of the solutions was determined by exposing C. albicans to 10 ml of each solution at room temperature for 4 hours. Subsequently, an aliquot of each solution was serial diluted onto agar plates and incubated for 48 hours at elevated temperatures. At the conclusion of the incubation period the plates are examined for the development of colonies. The log reduction was determined based on a comparison to the inoculum control. The following table provides the results of the in vitro studies.
Tm - Trademark 6 Additive 4 hour log reduction Inositol (0.5%) 1.1 Buffer control 0.8 The solution containing inositol showed an improvement in the activity against C.
albicans as compared to the buffer control.
Formulation Preserved Solution for rinsing, storage, reconsitituting enzyme tablets A formulation was prepared by dissolving Tricine, Allantoin, Inositol, Disodium edetate, and Polyoxyl 40 Hydrogenated Castor Oil in 80% of the water volume.
The pH of the solution was adjusted to 7.3 with 1 N sodium hydroxide. The tonicity of the solution was adjusted with sodium chloride and polyhexamethylene biguanide was added. The solution was diluted to volume with water.
Constituent Supplier % Weight/ Amount Volume Purified water to 80% 40 mL
Tricine Spectrum 1.0% 0.500 g Allantoin Spectrum 0.25% 0.125 g lnositol Spectrum 0.1% 0.050 g Edetate Disodium Spectrum 0.055% 0.0275 g Polyoxyl 40 TM Cremophor RH 0.1% 0.5 mL of 10%
Hydrogenated Castor Oil 40 from BASF Co.
Sodium Hydroxide, 1N as required for pH as required for pH
adjustment to 7.3 adjustment to 7.3 Purified Water to 98% Dilute to 49 mL
Sodium Chloride Fisher As required for As required for tonicity adjustment tonicity adjustment 285 mOsm 285 mOsm Polyhexamethylene- 20% w/w solution 0.0001% 50 uL of 0.1%
biguanide HCI available under the mark Cosmocil CQ from Avecia Purified Water Balance to 100% Dilute to 50 mL
This provides an example of a specific formulation of the present invention but does not fully illustrate the bounds or limits of the invention.
TM - Trademark Example 3A. Patent: (Sugars and Glycols with less than 0.1% chloride) An example of a formulation containing low salt, a buffer and cationic preservative follows:
Log Reduction Buffer Preservative Preservative Enhancer Wetting Agent 2.27 none PHMB 0.0001% none None 3.85 Bis-Tris Propane 0.2% PHMB 0.0001 % none Cremophor RH 40 4.40 Bis-Tris Propane 0.2% PHMB 0.0001% propylene glycol 3% Cremophor RH 40 4.40 Bis-Tris Propane 0.2% PHMB 0.0001 % sorbitol 5% Cremophor RH 40 4.40 Bis-Tris Propane 0.2% PHMB 0.0001% inositol 5% Cremophor RH 40 2.98 Opti-Free Express 0.68 Ciba Solo-care 2.99 B&L Renu Multiplus MPS
Column I shows the reduction of c. albicans at 4 hours using a typical antibacterial test. The data shows improved activity over the preservative alone; improved activity over the buffer control without sugar additive and improved activity over commercially available products Example 3B. Sugar/Glycol Preservative Efficacy Relationship to Salt Concentration Example 3B. Sugar/Glycol Preservative Efficacy Relationship to Salt Concentration Log Reduction Buffer Preservative Additive 2.53 none PHMB 0.0001 % none 1.34 Bis-Tris Propane 0.2% PHMB 0.0001 % sodium chloride 0.5%
3.42 Bis-Tris Propane 0.2% PHMB 0.0001% glycerin 0.5%
2.73 Bis-Tris Propane 0.2% PHMB 0.0001 % propylene glycol 0.5%
1.13 Bis-Tris Propane 0.2% PHMB 0.0001 % potassium chloride 0.5%
3.92 Bis-Tris Propane 0.2% PHMB 0.0001 % sorbitol 0.5%
3.23 Bis-Tris Propane 0.2% PHMB 0.0001 % mannitol 0.5%
3.06 Bis-Tris Propane 0.2% PHMB 0.0001% inositol 0.5%
3.72 Bis-Tris Propane 0.2% PHMB 0.0001 % dextrose 0.5%
This data shows that the antimicrobial activity of buffer with the sugar or glycol it greater than the preservative alone and that decreased acitivity at 0.5%
sodium chloride or 0.5% potassium chloride solutions occurs as well. Thus the surprising effect of the sugar derived preservative enhancers is displayed and the effects relationship to chloride concentration is demonstrated.
Example 3C. Solutions with less than 0.1% chloride specifically using glycerin Solutions with a cationic polymeric preservative (PHMB) sodium chloride and glycerin and a buffer were made as shown in the following table and the preservative efficacy was measured.
Log Sodium Reduction Buffer Preservative Chloride Glycerin 1.69 none PHMB 0.0001% none none 1.74 none PHMB 0.0001% 0.1% none 1.46 none PHMB 0.0001% 0.2% none 0.86 none PHMB 0.0001% 0.4% none 0.49 none PHMB 0.0001% 0.5% none 2.44 Bis-Tris Propane 0.2% PHMB 0.0001% none none 1.89 Bis-Tris Propane 0.2% PHMB 0.0001% 0.1% none 1.54 Bis-Tris Propane 0.2% PHMB 0.0001% 0.2% none 0.98 Bis-Tris Propane 0.2% PHMB 0.0001% 0.4% none 0.89 Bis-Tris Propane 0.2% PHMB 0.0001 % 0.5% none 2.46 Bis-Tris Propane 0.2% PHMB 0.0001% none 0.20%
2.41 Bis-Tris Propane 0.2% PHMB 0.0001% none 0.50%
The above date illustrates the effect of sodium chloride on preservative efficacy and the effect of glycerin in improving preservative efficacy in low salt solutions.
Example 3D. Experiment Showing Preservative Effect Inhibition is Buffer Dependent Solutions were made according to methods described supra with sodium phosphate as the buffer.
Log Reduction Buffer Preservative Tonicity Agent 0.79 Sodium Phosphate 0.2% PHMB 0.0001 % none 0.33 Sodium Phosphate 0.2% PHMB 0.0001 % Sodium Chloride 0.7%
This data illustrates the problem with sodium chloride is independent of buffer type.
Example 3E. The Lens Conditioning Properties of Saccharide Containing Formulations Solutions were formulated with sodium chloride, sorbitol and sucrose and then lenses were immersed in the resultant solutions and chiorohexidine gluconate was added. The lenses were exposed for 3 hours and the amount of the chiorohexidine deposited on the lens was measured.
Method: HPLC analysis for chlorhexidine gluconate 3.0 mL solution exposed to 1/2 lens TM
Matrix: 1 ppm CHG / 0.2% Bis-Tris Propane / 0.1 % Cremophor RH 40 Lens: Freshlook ColorBlends (45% phemfilcon A, 55% water) Wesley Jess Additive ug CHG per lens % Decrease None 4.0 67.3%
Sodium Chloride 3.6 59.3%
Sorbitol 3.0 50.7%
Sucrose 1.3 21.4%
1 ppm CHG Std in water %RSD through the entire experiment 2.9%
This test shows that the sugars used in the test have an ability to decrease the extent of preservative binding for of cationic preservatives when properly formulated.
Both sorbitol and sucrose solutions demonstrated efficacy in reducing preservative deposition.
TM - Trademark Example 3F
The following experiment demonstrates the effect of chloride concentration on the antimicrobial effectiveness of PHMB preservative solutions.
Log Reduction Buffer Preservative NaCl Additive Effect 1.05 Bis-Tris 0.2% PHMB 0.0001 % none none 54%
1.47 Bis-Tris 0.5% PHMB 0.0001 % none none 75%
0.77 Bis-Tris 0.2% PHMB 0.0001% 0.70% none 39%
2.39 Bis-Tris Propane 0.2% PHMB 0.0001 % none none 123%
2.32 Bis-Tris Propane 0.5% PHMB 0.0001 % none none 119%
0.91 Bis-Tris Propane 0.2% PHMB 0.0001 % 0.70% none 47%
1.27 Tricine 0.2% PHMB 0.0001% none none 65%
1.31 Tricine 0.5% PHMB 0.0001% none none 67%
0.62 Tricine 0.2% PHMB 0.0001% 0.70% none 32%
PRESERVATIVE ENILANCERS
Field of the Invention The present-invention relates to the field of ophthalmic solutions and their uses. In particular the invention relates to contact lens cleaning solutions, contact lens rinsing and storing solutions, solutions to deliver active pharmaceutical agents to the eye, solutions for disinfecting ophtalmic devices and the like.
Background The present invention relates to the field of ophthalmic solutions and especially to the aspects of preservative efficacy and comfort after prolonged use. These ophthalmic solutions have been used for some period of time and are available as over the counter products. Solutions that are used in direct contact with corneal tissue such as the delivery of active pharmaceutical agent to the eye, or indirectly, such as the cleaning, conditioning or storage of devices that will come in contact with corneal tissue, such as contact lenses, there is a need to insure that these solution do not introduce sources of bacterial or other microbial infection. Thus preservatives are included to reduce the viability of microbes in the solution and to lessen the chance of contamination of the solution by the user since many of the solutions are bought, opened, used, sealed and then reused.
State of the art preservative agents include polyhexamethylene biguanide (phmb), polyquad tr", chlorhexidine, and benzalkonium chloride, and the like, all of which at some concentration irritate corneal tissue and lead to user discomfort.
Therefore, a solution that employs a given amount of a preservative agent, but which is made more effective by addition of an agent that is not a preservative agent would be desired.
Summary of the Invention The present invention relates to improved ophthalmic solutions that employ inositol in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
The solutions specifically described herein have 0.001 to about 1 percent of inositol in combination with other active ingredients useful in ophthalmic solutions such as buffers, preservatives, surfactants, and antimicrobial agents, and with a low chloride concentration, less than about 0.2 percent by weight. It has been found, surprisingly that inositol, and other sugars including mannitol, sorbitol, sucrose, dextrose, glycerin and propylene glycol, effectively increase the antibacterial effect of preservatives in low salt (low chloride) conditions.
The preservatives that are specifically useful are cationic polymeric preservatives such as polyhexamethylene biguanide (phmb), polyquad tm, chlorhexidne, and benzalkonium chloride, as well as other cationic preservatives that may prove useful in the present invention as well. The cationic preservatives are used at effective amounts as preservatives, and in the instance of PHMB from 0.0001 percent by weight to higher levels of about 0.01 weight percent. Specifcally, The cationic polymeric preservative includes polymeric biguanides such as polymeric hexamethylene biguanides (PHMB), and combinations thereof. Such cationic polymeric biguanides, and water-soluble salts thereof, having the following formula:
X1 Z-NH C-NH-C-NHt Z-Xz NH NH
wherein Z is an organic divalent bridging group which may be the same or different throughout the polymer, n is on average at least 3, preferably on average 5 to 20, and X1 and X2 are NH2 and NH-C -NH-CN
NH
One preferred group of water-soluble polymeric biguanides will have number average molecular weights of at least 1,000 and more preferably will have number average molecular weights from 1,000 to 50,000. Suitable water-soluble salts of the free bases include, but are not limited to hydrochloride, borate, acetate, gluconate, sulfonate, tartrate and citrate salts.
The above-disclosed biguanides and methods of preparation are described in the literature. For example, U.S. Pat. No. 3,428,576 describes the preparation of polymeric biguanides from a diamine and salts thereof and a diamine salt of dicyanimide.
Most preferred are the polymeric hexamethylene biguanides, commercially available, for example, as the hydrochloride salt from Zeneca (Wilmington, Del.) under the trademark CosmocilTM CQ. Such polymers and water-soluble salts are referred to as polyhexamethylene (PHMB) or polyaminoptopyl biguanide (PAPB). The term polyhexamethylene biguanide, as used herein, is meant to encompass one or more biguanides have the following formula:
X1--E-Z-NH-C-NH-C-NH-}n z-X2 II II
NH NH
wherein Z, X1 and X2 are as defined above and n is from 1 to 500.
Depending on the manner in which the biguanides are prepared, the predominant compound falling within the above formula may have different X1 and X2 groups or the same groups, with lesser amounts of other compounds within the formula.
Such compounds are known and are disclosed in U.S. Pat. No. 4,758,595 and British 'O (12/38161 PCT/US01/46344 Patent 1,432,345. Preferably, the water-soluble salts are compounds where n has an average value of 2 to 15, most preferably 3 to 12.
It was found that an unexpected preservative efficacy was displayed when inositol was used in conjunction with the cationic preservative. The other components of the solution are used at levels known to those skilled in the art in order to improve the wearability of lenses and when used directly in the eye, to provide increased resistance to infection. Inositol used in ophthalmic solutions increases preservative efficacy in certain formulations, provides increased resistance to infection in corneal tissue, in certain formulations, and improves the quality of tears in certain formulations.
The formulations may also include buffers such as phosphates, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, and Tricine Surfactants that might be employed include polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils, but preerrably the polyethoxylated castor oils. These surfactants are commercially available.
The polyethoxylated castor oils are sold by BASF under the trademark Cremaphor.
Inositol, mannitol, sorbitol, sucrose, dextrose, glycerin, propylene glycol and the other agents used in the present invention are all commercially available, and well enough understood to be formulated into products within the scope of the invention by those skilled in the art.
The solutions of the present invention may contain other additives including but not limited to buffers, tonicity agents, demulcents, wetting agents, preservatives, sequestering agents (chelating agents), surface active agents, and enzymes.
Other aspects include adding to the solution from 0.001 to 1 weight percent chelating agent (preferably disodium EDTA) and/or additional microbicide, (preferably 0.00001 to 0.1 or 0.0000 1 to 0.01) weight percent polyhexamethylene biquanide (PHMBO, N-alkyl-2-pyrrolidone, chlorhexidine, polyquaternium- 1, hexetidine, bronopol, alexidine, low concentrations of hydrogen peroxide, and ophthalmologically acceptable salts thereof Ophthalmologically acceptable chelating agents useful in the present invention include amino carboxylic acid compounds or water-soluble salts thereof, including ethylenediaminetetraacetic acid, nitrilotriacetic acid, diethylenetriamine pentaacetic acid, hyd roxyethyl ethyl ened ia m i netriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol bis (beta-aminoethyl ether) in N, N, N', N' tetraacetic acid (EGTA), aminodiacetic acid and hydroxyethylamino diacetic acid. These acids can be used in the form of their water soluble salts, particularly their alkali metal salts.
Especially preferred chelating agents are the di-, tn- and tetra-sodium salts of ethylenediaminetetraacetic acid (EDTA), most preferably disodium EDTA
(Disodium Edetate).
Other chelating agents such as citrates and polyphosphates can also be used in the present invention. The citrates which can be used in the present invention include citric acid and its mono-, di-, and tri-alkaline metal salts. The polyphosphates which can be used include pyrophosphates, triphosphates, tetraphosphates, trimetaphosphates, tetrametaphosphates, as well as more highly condensed phosphates in the form of the neutral or acidic alkali metal salts such as the sodium and potassium salts as well as the ammonium salt.
The pH of the solutions should be adjusted to be compatible with the eye and the contact lens, such as between 6.0 to 8.0, preferably between 6.8 to 7.8 or between 7.0 to 7.6. Significant deviations from neutral (pH 7.3) will cause changes in the physical parameters (i.e. diameter) in some contact lenses. Low pH (pH less than 5.5) can cause burning and stinging of the eyes, while very low or very high pH (less than 3.0 or greater than 10) can cause ocular damage.
The additional preservatives employed in the present invention are known, such as polyhexamethylene biguanide, N-alkyl-2-pyrrolidone, chlorhexidine, polyhexamethylenebiguanide, alexidine, polyquaternium- 1, hexetidine, bronopol and a very low concentration of hydrogen peroxide, e.g., 30 to 200 ppm.
WO 02/38161 PCT/US01/.6344 The solutions of the invention are compatible with both rigid gas permeable and hydrophilic contact lenses during storage, cleaning, wetting, soaking, rinsing and disinfection.
A typical aqueous solution of the present invention may contain additional ingredients which would not affect the basic and novel characteristics of the active ingredients described earlier, such as tonicity agents, surfactants and viscosity inducing agents, which may aid in either the lens cleaning or in providing lubrication to the eye. Suitable tonicity agents include sodium chloride, potassium chloride, glycerol or mixtures thereof The tonicity of the solution is typically adjusted to approximately 240-310 milliosmoles per kilogram solution (mOsm/kg) to render the solution compatible with ocular tissue and with hydrophilic contact lenses. In one embodiment, the solution contains 0.01 to 0.2 weight percent sodium chloride.
The important factor is to keep the concentrations of such additives to a degree no greater than that would supply a chloride concentration of no greater than about 0.2 mole percent.
Suitable viscosity inducing agents can include lecithin or the cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose and methylcellulose in amounts similar to those for surfactants, above.
EXAMPLE I
TM
Formulations containing inositol (Spectrum) were prepared in a 0.2% phosphate buffer. The solutions were made isotonic with sodium chloride and preserved with polyhexamethylene biquanide at 0.0001 %. The pH was adjusted to 7.2 with either I
N sodium hydroxide or 1 N hydrochloric acid. The in vitro microbicidal activity of the solutions was determined by exposing C. albicans to 10 ml of each solution at room temperature for 4 hours. Subsequently, an aliquot of each solution was serial diluted onto agar plates and incubated for 48 hours at elevated temperatures. At the conclusion of the incubation period the plates are examined for the development of colonies. The log reduction was determined based on a comparison to the inoculum control. The following table provides the results of the in vitro studies.
Tm - Trademark 6 Additive 4 hour log reduction Inositol (0.5%) 1.1 Buffer control 0.8 The solution containing inositol showed an improvement in the activity against C.
albicans as compared to the buffer control.
Formulation Preserved Solution for rinsing, storage, reconsitituting enzyme tablets A formulation was prepared by dissolving Tricine, Allantoin, Inositol, Disodium edetate, and Polyoxyl 40 Hydrogenated Castor Oil in 80% of the water volume.
The pH of the solution was adjusted to 7.3 with 1 N sodium hydroxide. The tonicity of the solution was adjusted with sodium chloride and polyhexamethylene biguanide was added. The solution was diluted to volume with water.
Constituent Supplier % Weight/ Amount Volume Purified water to 80% 40 mL
Tricine Spectrum 1.0% 0.500 g Allantoin Spectrum 0.25% 0.125 g lnositol Spectrum 0.1% 0.050 g Edetate Disodium Spectrum 0.055% 0.0275 g Polyoxyl 40 TM Cremophor RH 0.1% 0.5 mL of 10%
Hydrogenated Castor Oil 40 from BASF Co.
Sodium Hydroxide, 1N as required for pH as required for pH
adjustment to 7.3 adjustment to 7.3 Purified Water to 98% Dilute to 49 mL
Sodium Chloride Fisher As required for As required for tonicity adjustment tonicity adjustment 285 mOsm 285 mOsm Polyhexamethylene- 20% w/w solution 0.0001% 50 uL of 0.1%
biguanide HCI available under the mark Cosmocil CQ from Avecia Purified Water Balance to 100% Dilute to 50 mL
This provides an example of a specific formulation of the present invention but does not fully illustrate the bounds or limits of the invention.
TM - Trademark Example 3A. Patent: (Sugars and Glycols with less than 0.1% chloride) An example of a formulation containing low salt, a buffer and cationic preservative follows:
Log Reduction Buffer Preservative Preservative Enhancer Wetting Agent 2.27 none PHMB 0.0001% none None 3.85 Bis-Tris Propane 0.2% PHMB 0.0001 % none Cremophor RH 40 4.40 Bis-Tris Propane 0.2% PHMB 0.0001% propylene glycol 3% Cremophor RH 40 4.40 Bis-Tris Propane 0.2% PHMB 0.0001 % sorbitol 5% Cremophor RH 40 4.40 Bis-Tris Propane 0.2% PHMB 0.0001% inositol 5% Cremophor RH 40 2.98 Opti-Free Express 0.68 Ciba Solo-care 2.99 B&L Renu Multiplus MPS
Column I shows the reduction of c. albicans at 4 hours using a typical antibacterial test. The data shows improved activity over the preservative alone; improved activity over the buffer control without sugar additive and improved activity over commercially available products Example 3B. Sugar/Glycol Preservative Efficacy Relationship to Salt Concentration Example 3B. Sugar/Glycol Preservative Efficacy Relationship to Salt Concentration Log Reduction Buffer Preservative Additive 2.53 none PHMB 0.0001 % none 1.34 Bis-Tris Propane 0.2% PHMB 0.0001 % sodium chloride 0.5%
3.42 Bis-Tris Propane 0.2% PHMB 0.0001% glycerin 0.5%
2.73 Bis-Tris Propane 0.2% PHMB 0.0001 % propylene glycol 0.5%
1.13 Bis-Tris Propane 0.2% PHMB 0.0001 % potassium chloride 0.5%
3.92 Bis-Tris Propane 0.2% PHMB 0.0001 % sorbitol 0.5%
3.23 Bis-Tris Propane 0.2% PHMB 0.0001 % mannitol 0.5%
3.06 Bis-Tris Propane 0.2% PHMB 0.0001% inositol 0.5%
3.72 Bis-Tris Propane 0.2% PHMB 0.0001 % dextrose 0.5%
This data shows that the antimicrobial activity of buffer with the sugar or glycol it greater than the preservative alone and that decreased acitivity at 0.5%
sodium chloride or 0.5% potassium chloride solutions occurs as well. Thus the surprising effect of the sugar derived preservative enhancers is displayed and the effects relationship to chloride concentration is demonstrated.
Example 3C. Solutions with less than 0.1% chloride specifically using glycerin Solutions with a cationic polymeric preservative (PHMB) sodium chloride and glycerin and a buffer were made as shown in the following table and the preservative efficacy was measured.
Log Sodium Reduction Buffer Preservative Chloride Glycerin 1.69 none PHMB 0.0001% none none 1.74 none PHMB 0.0001% 0.1% none 1.46 none PHMB 0.0001% 0.2% none 0.86 none PHMB 0.0001% 0.4% none 0.49 none PHMB 0.0001% 0.5% none 2.44 Bis-Tris Propane 0.2% PHMB 0.0001% none none 1.89 Bis-Tris Propane 0.2% PHMB 0.0001% 0.1% none 1.54 Bis-Tris Propane 0.2% PHMB 0.0001% 0.2% none 0.98 Bis-Tris Propane 0.2% PHMB 0.0001% 0.4% none 0.89 Bis-Tris Propane 0.2% PHMB 0.0001 % 0.5% none 2.46 Bis-Tris Propane 0.2% PHMB 0.0001% none 0.20%
2.41 Bis-Tris Propane 0.2% PHMB 0.0001% none 0.50%
The above date illustrates the effect of sodium chloride on preservative efficacy and the effect of glycerin in improving preservative efficacy in low salt solutions.
Example 3D. Experiment Showing Preservative Effect Inhibition is Buffer Dependent Solutions were made according to methods described supra with sodium phosphate as the buffer.
Log Reduction Buffer Preservative Tonicity Agent 0.79 Sodium Phosphate 0.2% PHMB 0.0001 % none 0.33 Sodium Phosphate 0.2% PHMB 0.0001 % Sodium Chloride 0.7%
This data illustrates the problem with sodium chloride is independent of buffer type.
Example 3E. The Lens Conditioning Properties of Saccharide Containing Formulations Solutions were formulated with sodium chloride, sorbitol and sucrose and then lenses were immersed in the resultant solutions and chiorohexidine gluconate was added. The lenses were exposed for 3 hours and the amount of the chiorohexidine deposited on the lens was measured.
Method: HPLC analysis for chlorhexidine gluconate 3.0 mL solution exposed to 1/2 lens TM
Matrix: 1 ppm CHG / 0.2% Bis-Tris Propane / 0.1 % Cremophor RH 40 Lens: Freshlook ColorBlends (45% phemfilcon A, 55% water) Wesley Jess Additive ug CHG per lens % Decrease None 4.0 67.3%
Sodium Chloride 3.6 59.3%
Sorbitol 3.0 50.7%
Sucrose 1.3 21.4%
1 ppm CHG Std in water %RSD through the entire experiment 2.9%
This test shows that the sugars used in the test have an ability to decrease the extent of preservative binding for of cationic preservatives when properly formulated.
Both sorbitol and sucrose solutions demonstrated efficacy in reducing preservative deposition.
TM - Trademark Example 3F
The following experiment demonstrates the effect of chloride concentration on the antimicrobial effectiveness of PHMB preservative solutions.
Log Reduction Buffer Preservative NaCl Additive Effect 1.05 Bis-Tris 0.2% PHMB 0.0001 % none none 54%
1.47 Bis-Tris 0.5% PHMB 0.0001 % none none 75%
0.77 Bis-Tris 0.2% PHMB 0.0001% 0.70% none 39%
2.39 Bis-Tris Propane 0.2% PHMB 0.0001 % none none 123%
2.32 Bis-Tris Propane 0.5% PHMB 0.0001 % none none 119%
0.91 Bis-Tris Propane 0.2% PHMB 0.0001 % 0.70% none 47%
1.27 Tricine 0.2% PHMB 0.0001% none none 65%
1.31 Tricine 0.5% PHMB 0.0001% none none 67%
0.62 Tricine 0.2% PHMB 0.0001% 0.70% none 32%
Claims (9)
1. An ophthalmic solution comprising 0.001 to 10 weight percent of a preservative enhancer chosen from the group consisting of: inositol; mannitol;
sorbitol; sucrose; dextrose; and at least 0.0001 weight percent of polyhexamethylene biguanide, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
sorbitol; sucrose; dextrose; and at least 0.0001 weight percent of polyhexamethylene biguanide, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
2. An ophthalmic solution comprising 0.001 to 10 weight percent of a preservative enhancer chosen from the group consisting of: inositol; mannitol;
sorbitol; sucrose; and dextrose; and at least 0.0001 weight percent of a polyhexamethylene biguanide, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
sorbitol; sucrose; and dextrose; and at least 0.0001 weight percent of a polyhexamethylene biguanide, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
3. The ophthalmic solution of claim 1, wherein the concentration of said polyhexamethylene biguianide is between 1 and 100 parts per million.
4. The ophthalmic solution of claim 1, further comprising a physiologically compatible buffer.
5. The ophthalmic solution of claim 4, further comprising a physiologically compatible buffer is selected from the group consisting of: phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, and Tricine.
6. The ophthalmic solution of claim 1, further comprising a wetting agent.
7. The ophthalmic solution of claim 6, wherein said wetting agent is selected from the group consisting of: polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils.
8. The ophthalmic solution of claim 1, further comprising a sequestering or chelating agent.
9. The ophthalmic solution of claim 8, wherein said sequestering or chelating agent is selected from the group consisting of: ethylenediaminetetraacetic acid, phosphonates, citrate, nitrilotriacetic acid, diethylenetriamine pentaacetic acid, hydroxyethylethylenediaminetriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol bis (beta-aminoethyl ether) in N, N, N', N' tetraacetic acid (EGTA), aminodiacetic acid, hydroxyethylamino diacetic acid, and water-soluble salts thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24687000P | 2000-11-08 | 2000-11-08 | |
US60/246,870 | 2000-11-08 | ||
PCT/US2001/046344 WO2002038161A1 (en) | 2000-11-08 | 2001-11-08 | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2428985A1 CA2428985A1 (en) | 2002-05-16 |
CA2428985C true CA2428985C (en) | 2011-05-24 |
Family
ID=22932591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2428985A Expired - Lifetime CA2428985C (en) | 2000-11-08 | 2001-11-08 | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060142169A1 (en) |
EP (1) | EP1339418B1 (en) |
JP (1) | JP4084997B2 (en) |
CN (1) | CN1245166C (en) |
AT (1) | ATE443749T1 (en) |
AU (3) | AU2002227206B2 (en) |
CA (1) | CA2428985C (en) |
CY (1) | CY1111043T1 (en) |
DE (1) | DE60140007D1 (en) |
DK (1) | DK1339418T3 (en) |
ES (1) | ES2330617T3 (en) |
PT (1) | PT1339418E (en) |
WO (1) | WO2002038161A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129083A1 (en) * | 1997-11-26 | 2003-07-10 | Advanced Medical Optics, Inc. | Multi purpose contact lens care compositions including propylene glycol or glycerin |
US9913474B2 (en) | 2000-11-08 | 2018-03-13 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US20070104744A1 (en) * | 2000-11-08 | 2007-05-10 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing forms of vitamin b |
US9308264B2 (en) | 2000-11-08 | 2016-04-12 | Fxs Ventures, Llc | Ophthalmic contact lens solutions containing forms of vitamin B |
US9492582B2 (en) * | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
EP1339278B1 (en) | 2000-11-29 | 2004-12-08 | Novartis AG | Aqueous disinfecting systems |
US7550418B2 (en) | 2002-12-13 | 2009-06-23 | Novartis Ag | Lens care composition and method |
CA2545962A1 (en) * | 2003-12-09 | 2005-07-07 | Alcon, Inc. | Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |
US20050202983A1 (en) * | 2004-03-12 | 2005-09-15 | Erning Xia | Prevention of loss of tight cell junctions using carbohydrate-containing compositions |
DE102004037598A1 (en) * | 2004-08-03 | 2006-02-23 | Prontomed Gmbh | Medium, useful as mouth and throat rinsing solution or mouth spray, comprises microbicide aqueous solution comprising a linear biguanide polymer and/or water-soluble salt of microbicide in combination with a sweetener |
US8569367B2 (en) | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
JP4565500B2 (en) * | 2005-01-18 | 2010-10-20 | 株式会社シード | Contact lens solution |
JP5135526B2 (en) * | 2005-06-27 | 2013-02-06 | 株式会社メニコンネクト | Contact lens solution |
US20070048345A1 (en) * | 2005-08-31 | 2007-03-01 | Kimberly-Clark Worldwide, Inc. | Antimicrobial composition |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US7858000B2 (en) | 2006-06-08 | 2010-12-28 | Novartis Ag | Method of making silicone hydrogel contact lenses |
AU2007272558B2 (en) * | 2006-07-12 | 2010-12-09 | Novartis Ag | Actinically crosslinkable copolymers for manufacturing contact lenses |
JP5033380B2 (en) * | 2006-08-30 | 2012-09-26 | ディバーシー株式会社 | Disinfectant composition and disinfectant cleaning composition for tableware, cooking utensils, food processing plant or kitchen, and sterilization method or disinfecting cleaning method for tableware, cooking utensils, food processing plant or kitchen facilities using the same |
AR064286A1 (en) * | 2006-12-13 | 2009-03-25 | Quiceno Gomez Alexandra Lorena | PRODUCTION OF OPHTHALMIC DEVICES BASED ON POLYMERIZATION BY PHOTOINDUCIDED SCALE GROWTH |
JP5414175B2 (en) * | 2007-02-06 | 2014-02-12 | 三菱電機株式会社 | Method and apparatus for deodorizing clothing |
TWI419719B (en) | 2007-08-31 | 2013-12-21 | Novartis Ag | Contact lens products |
ATE540327T1 (en) | 2007-08-31 | 2012-01-15 | Novartis Ag | CONTACT LENS PACKAGING SOLUTIONS |
EP2263699B1 (en) | 2008-03-12 | 2014-03-12 | Menicon Co., Ltd. | Solution composition for contact lenses |
CN102190591A (en) * | 2010-03-12 | 2011-09-21 | 陈郁 | Metal complex, preparation method and application thereof |
EP2612664A4 (en) * | 2010-09-02 | 2014-03-19 | Menicon Co Ltd | Stabilized polyphenol solution and method for stabilizing polyphenol solution |
KR101906631B1 (en) * | 2011-06-23 | 2018-10-10 | 산텐 세이야꾸 가부시키가이샤 | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol |
US8957048B2 (en) | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
CA2858574C (en) | 2011-12-07 | 2017-05-30 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
CN107106483B (en) | 2014-11-25 | 2021-04-16 | 阿勒根公司 | Stabilized omega-3 ophthalmic compositions |
EP3543004B1 (en) | 2015-12-03 | 2020-08-26 | Alcon Inc. | Contact lens packaging solutions |
US10632202B2 (en) | 2016-03-04 | 2020-04-28 | Johnson & Johnson Consumer Inc. | Preservative containing compositions |
GB201621050D0 (en) * | 2016-12-12 | 2017-01-25 | Provita Eurotech Ltd | Antimicrobial compositions |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1432345A (en) | 1920-09-15 | 1922-10-17 | Powers Accounting Machine Comp | Rotary selector or analyzer |
US2976576A (en) | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
US3429576A (en) | 1965-08-28 | 1969-02-25 | Yoshiaki Ikeda | Golf club having level indicating means and weight means |
GB1152243A (en) * | 1965-11-26 | 1969-05-14 | Ici Ltd | Process for the Manufacture of Polymeric Diguanides |
US3503393A (en) * | 1966-05-19 | 1970-03-31 | Blease Anaesthetic Equip Ltd | Patient controlled respiratory apparatus |
DE1667942B2 (en) | 1967-03-15 | 1977-05-12 | Ceskoslovenska Akademie Ved, Prag | METHOD AND DEVICE FOR STERILE STORAGE OF OBJECTS FROM SWELLED HYDOGELS, IN PARTICULAR OF CONTACT LENSES |
US3689673A (en) * | 1970-11-10 | 1972-09-05 | Barnes Hind Pharm Inc | The process of soaking and sterilizing hydrophilic soft contact lenses with chlorhexidene |
US3755561A (en) * | 1971-03-22 | 1973-08-28 | Burton Parsons & Co Inc | Bactericidal contact lens solution |
FR2199470B1 (en) | 1971-06-21 | 1977-12-30 | Wave Energy Systems | |
US3873696A (en) * | 1972-01-31 | 1975-03-25 | Allergan Pharma | Cleaning and sterilizing soft contact lens |
US4022834A (en) * | 1972-03-16 | 1977-05-10 | A/S Farmaceutisk Industri | Antibacterially active hexamethylene-bis-biguanides |
NO135634C (en) | 1972-03-16 | 1977-05-04 | Farmaceutisk Ind As | |
US3888782A (en) * | 1972-05-08 | 1975-06-10 | Allergan Pharma | Soft contact lens preserving solution |
US3876768A (en) | 1972-11-06 | 1975-04-08 | Hydrophilics Int Inc | Sterilization of soft, hydrophilic acrylate and methacrylate copolymer materials |
US3911107A (en) * | 1972-12-18 | 1975-10-07 | Flow Pharma Inc | Iodine composition and dissipating solution |
US3910296A (en) | 1973-04-20 | 1975-10-07 | Allergan Pharma | Method of removing proteinaceous deposits from contact lenses |
US3943251A (en) * | 1973-06-27 | 1976-03-09 | Medow Norman B | Ophthamological use of hydrastis compounds |
US4029817A (en) * | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
GB1562899A (en) | 1975-06-17 | 1980-03-19 | Wellcome Found | Pharmaceutical compositions containing substituted 9-( -d-arabnofuranosyl)purine-5'-phosphate and salts thereof |
US4046706A (en) | 1976-04-06 | 1977-09-06 | Flow Pharmaceuticals, Inc. | Contact lens cleaning composition |
IT1063325B (en) | 1976-05-19 | 1985-02-11 | Brevitex Ets Exploit | DEVICE FOR SPREADING THE CROSSBODY FRAMES |
US4136173A (en) | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
US4209817A (en) | 1978-03-15 | 1980-06-24 | Square D Company | Circuit breaker having an electronic fault sensing and trip initiating unit |
US4394381A (en) * | 1979-04-13 | 1983-07-19 | George F. And Irene Sherrill 1978 Trust No. 1 | Method for the relief of pain |
US4361549A (en) * | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
JPS599600B2 (en) * | 1980-11-14 | 1984-03-03 | 花王株式会社 | Shampoo - Composition |
US4361548A (en) * | 1980-11-28 | 1982-11-30 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution (polymeric) |
US4361458A (en) | 1981-02-13 | 1982-11-30 | The Wurlitzer Company | Piano soundboard and method of making same |
US4354952A (en) | 1981-03-12 | 1982-10-19 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution comprising chlorhexidine and salts thereof |
JPS5810517A (en) | 1981-07-13 | 1983-01-21 | Santen Pharmaceut Co Ltd | Ophthalmic solution containing non-steroid antiphlogistic agent as main component |
US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
US4820352A (en) * | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
JPS6038323A (en) * | 1983-08-10 | 1985-02-27 | Sankyo Co Ltd | Ophthalmic anti-inflammatory agent |
US4758595A (en) * | 1984-12-11 | 1988-07-19 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US4748189A (en) | 1985-04-19 | 1988-05-31 | Ciba-Geigy Corporation | Ophthalmic solutions and methods for improving the comfort and safety of contact lenses |
USRE32672E (en) | 1985-09-09 | 1988-05-24 | Allergan, Inc. | Method for simultaneously cleaning and disinfecting contact lenses using a mixture of peroxide and proteolytic enzyme |
JPH0696521B2 (en) * | 1986-01-31 | 1994-11-30 | 千寿製薬株式会社 | Ocular hypotensive agent for topical ocular administration |
JPH0672866B2 (en) * | 1986-03-19 | 1994-09-14 | 本田技研工業株式会社 | Oxygen concentration detector |
EP0258672A3 (en) | 1986-08-07 | 1989-07-26 | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG | Cationic surfactants and pharmaceutical compositions containing them |
US4863900A (en) | 1987-01-15 | 1989-09-05 | The Research Foundation Of State University Of New York | Method for reducing viral transmission with poly-L-histidine |
US4783488A (en) | 1987-01-31 | 1988-11-08 | Bausch & Lomb Incorporated | Contact lens wetting solution |
US5246708A (en) | 1987-10-28 | 1993-09-21 | Pro-Neuron, Inc. | Methods for promoting wound healing with deoxyribonucleosides |
US5624958A (en) | 1987-12-31 | 1997-04-29 | Isaacs; Charles E. | Disinfecting contact lenses |
US5192535A (en) * | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
JPH01211595A (en) | 1988-02-18 | 1989-08-24 | Kikkoman Corp | Novel n-acetyl-beta-d-glucosamine derivative, production thereof and utilization thereof to reagent for measuring n-acetyl-beta-d-glucosamidase activity |
US5607698A (en) * | 1988-08-04 | 1997-03-04 | Ciba-Geigy Corporation | Method of preserving ophthalmic solution and compositions therefor |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US4891423A (en) | 1989-03-20 | 1990-01-02 | Stockel Richard F | Polymeric biguanides |
US5175161A (en) | 1989-04-06 | 1992-12-29 | Sankyo Company, Limited | Occular hypotensive agents |
JP2893537B2 (en) | 1989-07-20 | 1999-05-24 | 東海電化工業株式会社 | Histidine-hydrogen peroxide adduct and method for producing the same |
EP0485475B1 (en) | 1989-08-01 | 1996-06-12 | Schering Corporation | Contact lens disinfecting system |
US4988710A (en) | 1989-08-25 | 1991-01-29 | Washington University | Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins |
US5279673A (en) | 1990-01-05 | 1994-01-18 | Allergan, Inc. | Methods to disinfect contact lenses |
US4997626A (en) * | 1990-01-05 | 1991-03-05 | Allergan, Inc. | Methods to disinfect contact lenses |
US5078908A (en) * | 1989-10-02 | 1992-01-07 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
US5300296A (en) * | 1989-11-06 | 1994-04-05 | Frank J. Holly | Antimicrobial agent for opthalmic formulations |
GB9002422D0 (en) | 1990-02-03 | 1990-04-04 | Boots Co Plc | Anti-microbial compositions |
US5174872A (en) * | 1990-06-08 | 1992-12-29 | Technicon Instruments Corporation | Metal-free buffer for ion selective electrode-based assays |
US5102670A (en) | 1990-09-14 | 1992-04-07 | Abraham Nader G | Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels |
EP0563250A1 (en) | 1990-12-19 | 1993-10-06 | Allergan, Inc. | Compositions and methods for contact lens disinfecting |
AU653768B2 (en) | 1990-12-27 | 1994-10-13 | Advanced Medical Optics, Inc. | Method and composition for disinfecting contact lenses |
NZ242358A (en) | 1991-05-10 | 1994-03-25 | Allergan Inc | Use of thiol compounds to inhibit deposits on a contact lens |
US5439572A (en) * | 1991-12-02 | 1995-08-08 | Isoclear, Inc. | Lens protective encasement packet |
US5387394A (en) | 1992-06-29 | 1995-02-07 | Allergan, Inc. | Ophthalmic compositions and methods for preserving and using same |
WO1994021774A1 (en) | 1993-03-18 | 1994-09-29 | Polymer Technology Corporation | Alcohol-containing abrasive composition for cleaning contact lenses |
DE4345199C2 (en) | 1993-05-22 | 1995-10-12 | Asta Medica Ag | Use of dihydrolipoic acid to suppress intolerance reactions in the border area of implants with living body tissue |
DE59406509D1 (en) * | 1993-05-26 | 1998-08-27 | Fresenius Ag | ANTI-INFECTIVE |
US5968904A (en) | 1993-06-04 | 1999-10-19 | Demegen, Inc. | Modified arginine containing lytic peptides and method of making the same by glyoxylation |
US5561107A (en) * | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
IL109762A0 (en) | 1993-06-18 | 1994-08-26 | Allergan Inc | Method for treating hypoxia-associated ocular complications |
US5661130A (en) * | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
US5449658A (en) * | 1993-12-07 | 1995-09-12 | Zeneca, Inc. | Biocidal compositions comprising polyhexamethylene biguanide and EDTA, and methods for treating commercial and recreational water |
US5591773A (en) | 1994-03-14 | 1997-01-07 | The Trustees Of Columbia University In The City Of New York | Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters |
US5361287A (en) | 1994-03-29 | 1994-11-01 | B&W Fuel Company | Nuclear fuel assembly lower end fitting |
AU704591B2 (en) * | 1994-04-04 | 1999-04-29 | William R. Freeman | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
US5674450A (en) | 1994-04-28 | 1997-10-07 | Johnson & Johnson Medical, Inc. | Vapor sterilization using a non-aqueous source of hydrogen peroxide |
US5547990A (en) | 1994-05-20 | 1996-08-20 | Lonza, Inc. | Disinfectants and sanitizers with reduced eye irritation potential |
US5494937A (en) | 1994-07-22 | 1996-02-27 | Alcon Laboratories, Inc. | Saline solution for treating contact lenses |
WO1996003158A1 (en) | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
WO1996006603A1 (en) | 1994-08-26 | 1996-03-07 | Alcon Laboratories, Inc. | Polyalkylene oxide containing quaternary ammonium antimicrobial agents |
EP1089078B1 (en) | 1994-10-20 | 2007-02-28 | Sysmex Corporation | Reagent and method for analyzing solid components in urine |
US5739178A (en) | 1995-05-15 | 1998-04-14 | Allergan | Polymer, article and method for inhibiting the growth of ocular pathogens in eye care products |
US5718895A (en) * | 1995-11-16 | 1998-02-17 | Alcon Laboratories, Inc. | Enzymes with low isoelectric points for use in contact lens cleaning |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
US5965736A (en) | 1996-01-16 | 1999-10-12 | Lumigen, Inc. | Compositions and methods for generating red chemiluminescence |
DE69630539T2 (en) | 1996-01-22 | 2004-08-19 | Bausch & Lomb Inc. | TWO-STAGE SYSTEM FOR NEUTRALIZATION OF IODINE IN THE TREATMENT OF CONTACT LENSES |
CA2242660A1 (en) | 1996-02-16 | 1997-08-21 | The Regents Of The University Of California | Antimicrobial peptides and methods of use |
BR9708106A (en) | 1996-03-18 | 1999-07-27 | Bio Lab Inc | Clarifying water composition |
EP0896618B1 (en) | 1996-04-29 | 2007-06-20 | Novozymes A/S | Non-aqueous, liquid, enzyme-containing compositions |
US6358897B1 (en) * | 1996-06-07 | 2002-03-19 | Alcon Laboratories, Inc. | Alkyl trypsin compositions and methods of use in contact lens cleaning and disinfecting systems |
JPH1059846A (en) | 1996-06-10 | 1998-03-03 | Kikkoman Corp | Preventive or remedy for cararacta |
US5719110A (en) * | 1996-08-14 | 1998-02-17 | Allergan | Contact lens care compositions with inositol phosphate components |
JP3698832B2 (en) * | 1996-10-08 | 2005-09-21 | 株式会社メニコン | Contact lens solution |
US5958984A (en) | 1996-10-10 | 1999-09-28 | Devillez; Richard L. | Method and composition for skin treatment |
JP3829380B2 (en) | 1996-12-18 | 2006-10-04 | 住友化学株式会社 | Pest repellent and pest repellent method |
US5945446A (en) | 1997-02-10 | 1999-08-31 | Laubc Biochemicals, Corporation | Process for preparing synthetic soil-extract materials and medicaments based thereon |
US6022732A (en) | 1997-04-09 | 2000-02-08 | Allergan | Hydrogen peroxide destroying compositions and methods of using same |
RU2127100C1 (en) | 1997-04-17 | 1999-03-10 | Борзенок Сергей Анатольевич | Ocular drops "pyrotonik" |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US5925320A (en) | 1997-06-04 | 1999-07-20 | Jones; John P. | Air purification system |
WO1999023887A1 (en) | 1997-11-10 | 1999-05-20 | Novo Nordisk A/S | Antimicrobial activity of laccases |
JPH11137649A (en) | 1997-11-10 | 1999-05-25 | Tomey Technology Kk | Method for cleaning and disinfecting contact lens |
BR9814180A (en) | 1997-11-12 | 2000-10-03 | Bausch & Lomb | Method and solution for disinfecting and / or cleaning contact lenses. |
CN1278863A (en) * | 1997-11-12 | 2001-01-03 | 博士伦公司 | Disinfecting contact lenses with polyquaterniums and polymeric biguanides |
US6056920A (en) | 1997-12-12 | 2000-05-02 | Vertex Pharmaceuticals Incorporated | Process for identifying a solvent condition suitable for determining a biophysical property of a protein |
JPH11249087A (en) | 1997-12-18 | 1999-09-17 | Tome:Kk | Light agent for contact lens |
JP3883739B2 (en) * | 1998-05-22 | 2007-02-21 | 株式会社メニコン | Contact lens bactericidal solution |
JP2000016965A (en) | 1998-06-29 | 2000-01-18 | Mitsubishi Gas Chem Co Inc | Production of hydroxyalkylacrylic ester or methacrylic acid ester modified with caprolactone |
US6117869A (en) | 1998-08-04 | 2000-09-12 | Warner-Lambert Company | Compounds for and methods of inhibiting matrix metalloproteinases |
US6162393A (en) * | 1998-08-06 | 2000-12-19 | Ndt, Inc. | Contact lens and ophthalmic solutions |
KR20010031258A (en) | 1998-08-21 | 2001-04-16 | 요시다 쇼지 | Compositions for contact lenses |
US6309596B1 (en) | 1998-12-15 | 2001-10-30 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine |
US7678836B2 (en) | 1999-11-04 | 2010-03-16 | Fxs Ventures, Llc | Method for rendering a contact lens wettable |
US6153563A (en) | 1999-11-10 | 2000-11-28 | Lithchem International | Pouched ingredients for preparing greases |
US8557868B2 (en) | 2000-11-04 | 2013-10-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions using low molecular weight amines |
US6550862B2 (en) * | 2001-06-14 | 2003-04-22 | Cosco Management, Inc. | Juvenile vehicle seat cup holder |
US6624203B1 (en) | 2001-11-08 | 2003-09-23 | Francis X. Smith | Nucleic acid bases used in ophthalmic solutions |
US6617291B1 (en) * | 2001-11-08 | 2003-09-09 | Francis X. Smith | Ophthalmic and contact lens solutions |
-
2001
- 2001-11-08 DK DK01993467T patent/DK1339418T3/en active
- 2001-11-08 AU AU2002227206A patent/AU2002227206B2/en not_active Ceased
- 2001-11-08 CA CA2428985A patent/CA2428985C/en not_active Expired - Lifetime
- 2001-11-08 WO PCT/US2001/046344 patent/WO2002038161A1/en active Application Filing
- 2001-11-08 JP JP2002540744A patent/JP4084997B2/en not_active Expired - Fee Related
- 2001-11-08 CN CNB018218172A patent/CN1245166C/en not_active Expired - Fee Related
- 2001-11-08 US US10/544,151 patent/US20060142169A1/en active Granted
- 2001-11-08 EP EP01993467A patent/EP1339418B1/en not_active Expired - Lifetime
- 2001-11-08 US US10/544,151 patent/US9492581B2/en not_active Expired - Fee Related
- 2001-11-08 ES ES01993467T patent/ES2330617T3/en not_active Expired - Lifetime
- 2001-11-08 AT AT01993467T patent/ATE443749T1/en active
- 2001-11-08 AU AU2720602A patent/AU2720602A/en active Pending
- 2001-11-08 DE DE60140007T patent/DE60140007D1/en not_active Expired - Lifetime
- 2001-11-08 PT PT01993467T patent/PT1339418E/en unknown
-
2006
- 2006-09-07 AU AU2006207883A patent/AU2006207883B2/en not_active Ceased
-
2009
- 2009-10-14 CY CY20091101065T patent/CY1111043T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP4084997B2 (en) | 2008-04-30 |
JP2004512904A (en) | 2004-04-30 |
DE60140007D1 (en) | 2009-11-05 |
WO2002038161A1 (en) | 2002-05-16 |
AU2006207883A1 (en) | 2006-09-28 |
EP1339418A4 (en) | 2005-06-08 |
PT1339418E (en) | 2009-10-30 |
AU2002227206B2 (en) | 2006-09-21 |
CN1486188A (en) | 2004-03-31 |
AU2006207883B2 (en) | 2009-08-06 |
CY1111043T1 (en) | 2015-06-11 |
DK1339418T3 (en) | 2009-12-14 |
AU2720602A (en) | 2002-05-21 |
EP1339418B1 (en) | 2009-09-23 |
EP1339418A1 (en) | 2003-09-03 |
US20060142169A1 (en) | 2006-06-29 |
US9492581B2 (en) | 2016-11-15 |
CA2428985A1 (en) | 2002-05-16 |
CN1245166C (en) | 2006-03-15 |
ES2330617T3 (en) | 2009-12-14 |
ATE443749T1 (en) | 2009-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2428985C (en) | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers | |
AU2002227206A1 (en) | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers | |
US5593637A (en) | Method and composition for disinfecting contact lenses | |
US9492582B2 (en) | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers | |
EP1733014B1 (en) | Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions | |
US6369112B1 (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol | |
EP1337262B1 (en) | Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative | |
EP1572253B1 (en) | Lens care composition and method | |
US20110212885A1 (en) | Ophthalmic and contact lens solutions containing peptides as preservative | |
US10531663B2 (en) | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers | |
EP2262521B1 (en) | Ophthalmic compositions comprising a dipeptide with a glycine moiety | |
IE920220A1 (en) | Method and composition for disinfecting contact lenses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |